rheumatoid%20arthritis
RHEUMATOID ARTHRITIS

Rheumatoid arthritis is a systemic autoimmune rheumatic disorder of unknown etiology.
It is the most common form of inflammatory arthritis.
Patient usually complains of joint pain and/or swelling with morning stiffness that lasts for more than an hour.

Goals of treatment are clinical & radiological remission of disease and to reduce functional limitations & permanent joint damage.

Drug Information

Indication: Acute & chronic treatment of signs & symptoms of osteoarthritis (OA) & RA; ankylosing spondylitis ...

Indication: Management of acute pain in adults & treatment of primary dysmenorrhea. Relief of acute & chronic pain...

Indication: Signs & symptoms of arthritis deformans, periarthritis humero-scapularis, tendinitis, peritendinitis, hume...

Indication: Signs & symptoms & inhibiting the progression of structural damage in moderately to severely active rh...

Dosage: OA 7.5 mg daily, may be increased to 15 mg daily. RA Initially 15 mg daily, may be reduced to 7.5 mg daily. An

Dosage: Adult RA Initially 3 mg/kg IV infusion over 2-hr, followed by additional 3 mg/kg doses at 2 & 6 wk after t

Indication: In combination w/ methotrexate (MTX) for treatment of moderate to severe active rheumatoid arthritis (RA) in a...

Indication: Moderate to severe pain.

Indication: Adult patients w/ moderately to severely active RA who had an inadequate response or intolerance to methotrexa...

Indication: Treatment of early & established, moderate to severe active RA in adult patients, given alone or in combin...

1  /  19
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 18 Dec 2018
The use of ixekizumab to selectively target interleukin-17A (IL-17A) in disease-modifying antirheumatic drug-naïve patients with ankylosing spondylitis yields improvements in disease activity, health-related quality of life, day-to-day physical activity, and bone marrow oedema of the spine and sacroiliac joint, according to the results of the phase III COAST-V study.
10 Jan 2019
Only a few sonographic enthesitis scoring instruments developed for spondyloarthritis (SpA) have been validated in psoriatic arthritis (PsA), and none of them passed the Outcome Measures in Rheumatology (OMERACT) filter in patients with PsA, according to a systematic review.